Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
-	Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil (as fumerate)	Stribild®	For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to the three antiretroviral agents in Stribild®.	Rapid review complete	20th May 2013
-	Empagliflozin	Jardiance®	Add-on combination therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.	Rapid review complete	17th June 2014
21030	Empagliflozin	Jardiance®	For the treatment of symptomatic chronic heart failure with reduced ejection fraction.	NCPE Assessment Process Complete	28th April 2022
22068	Empagliflozin	Jardiance®	For the treatment of symptomatic chronic heart failure with left ventricular ejection fraction >40%	Rapid review complete	20th October 2023
-	Emtricitabine / tenofovir disoproxil fumarate	Truvada®	In combination with safer sex practices for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.	Awaiting Applicant submission	18th July 2017
-	Emtricitabine/tenofovir alafenamide	Descovy®	In combination with other antiretroviral agents (ARVs) for the treatment of adults and adolescents (≥12 years; body weight ≥35 kg) infected with human immunodeficiency virus (HIV) type 1	Rapid review complete	26th April 2016
-	Emtricitabine/tenofovir disoproxil	TEVA®	For pre-exposure prophylaxis in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults in high risk	Rapid review complete	22nd December 2017
24011	Enalapril maleate	Aqumeldi®	For the treatment of heart failure in children and adolescents from birth to less than 18 years of age.	Rapid Review complete	12th April 2024
20037	Encorafenib	Braftovi®	In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy	Assessment process complete	28th January 2022
-	Encorafenib, binimetinib	Braftovi®, Mektovi®	For the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.	Rapid review complete	23rd January 2019
22024	Enfortumab vedotin	Padcev®	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor	NCPE Assessment Process Complete	14th March 2024
21038	Entrectinib	Rozlytrek®	As monotherapy for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors	Rapid review complete	28th September 2021
22055	Entrectinib	Rozlytrek®	As monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor and who have no satisfactory treatment options	Rapid review complete	29th September 2022
-	Enzalutamide	Xtandi®	First line treatment of adult men with mCRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated	Assessment process complete	22nd June 2015
21022	Enzalutamide	Xtandi®	For the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.	Rapid review complete	7th July 2021
18056	Enzalutamide	Xtandi®	For the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).	Assessment process complete	24th May 2022
-	Enzalutamide	Xtandi®	For the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.	Assessment process complete	10th April 2014
24010	Epcoritamab	Tepkinly®	Epcoritamab (Tepkinly®) is indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Rapid Review Complete	15th April 2024
-	Epoprostenol	Veletri®	For the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO FC III–IV symptoms to improve exercise capacity	Rapid review complete	7th February 2017
22052	Eptinezumab	Vyepti®	For the prophylaxis of migraine in adults who have at least four migraine days per month	Rapid review complete	20th October 2023
-	Erenumab	Aimovig®	For the treatment of chronic and episodic migraine in adults who have at least 4 migraine days per month when initiating treatment with erenumab.	Assessment process complete	30th September 2019
-	Eribulin	Halaven®	For the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.	Assessment process complete	7th December 2012
-	Ertugliflozin	Steglatro®	For the treatment of the treatment 2 diabetes mellitus (T2DM) in individuals 18 years and over to improve glycaemic control.	Rapid review complete	21st May 2018
19055	Esketamine	Spravato®	In combination with a SSRI or SNRI is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current depressive episode	Assessment process complete	9th March 2021
-	Eslicarbazepine	Zebinix®	For the treatment of Epilepsy	Rapid review complete	1st September 2009
20013	Estradiol	Oestrogel® Pump Gel	For: Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women; Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.	Rapid review complete	9th April 2020
22071	Estriol	Blissel®	Estriol (Blissel®) 50 micrograms per gram is indicated for local treatment of vaginal dryness in post- menopausal women with vaginal atrophy.	Rapid Review Complete	23rd January 2023
-	Etanercept	Benepali®	A biosimilar of the TNF-α inhibitor Etanercept (Enbrel®) for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, axial spondylitis and plaque psoriasis.	Rapid review complete	30th May 2016
-	Etelcalcitide	Parsabiv®	For the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.	Rapid review complete	1st September 2017
-	Everolimus	Afinitor®	Treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor	Rapid review complete	15th October 2012
-	Everolimus	Votubia®	For the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.	Rapid review complete	26th April 2017
-	Everolimus	Votubia®	For the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery	Rapid review complete	14th October 2011
-	Evolocumab	Repatha®	For both primary hypercholesterolaemia and mixed dyslipidaemia and heterozygous familial hypercholesterolaemia.	Assessment process complete	16th May 2018
-	Exenatide	Bydureon®	For the treatment of type II diabetes mellitus combined with Metformin, Sulphonylurea, Thiazolidinedione, Metform and SU and Metformn and TZD in adults who have not acheived glycaemic control on maximally tolerated doses of these oral therapies.	Rapid review complete	9th June 2011
-	Fampridine	Fampyra®	For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).	Assessment process complete	17th August 2012
22060	Faricimab	Vabysmo ®	For the treatment of adult patients with neovascular (wet) age-related macular degeneration.	Awaiting full HTA submission from Applicant	3rd October 2023
22061	Faricimab	Vabysmo ®	For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO).	Awaiting full HTA submission from Applicant	3rd October 2023
21069	Fedratinib	Inrebic®	For the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis who are JAK inhibitor–naive or have been treated with ruxolitinib.	Rapid Review Complete	20th January 2022
23048	Fenfluramine (Fintepla®)	Fintepla®	Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older).	Awaiting full HTA submission from Applicant	7th November 2023
23051	Fenfluramine	Fintepla®	Fenfluramine (Fintepla®) is indicated for patients (two years of age and older) with Lennox-Gastaut Syndrome as an add-on therapy to other anti-epileptic medicines.	Awaiting full HTA submission from Applicant	7th November 2023
-	Ferric maltol	Feraccru®	For the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) in adult patients.	Assessment process complete	6th September 2016
-	Ferumoxytol	Rienso®	For the treatment of iron deficiency anaemia in adult patients with chronic kidney disease (CKD).	Assessment process complete	17th August 2012
24005	Fezolinetant	Veoza™	Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause.	Awaiting full HTA submission from Applicant	24th April 2024
-	Fidaxomicin	Dificlir®	For the treatment of CDI also known as CDAD in adult patients. Rapid Review	Assessment process complete	5th February 2013
20047	Filgotinib	Jyseleca®	As monotherapy or in combination with methotrexate for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs.	Rapid Review Complete	16th November 2020
21048	Filgotinib	Jyseleca®	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.	Assessment process complete	10th December 2021
22012	Finerenone	Kerendia®	For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.	NCPE Assessment Process Complete	22nd August 2023
23077	Finerenone	Kerendia®	Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (with albuminuria) associated with type 2 diabetes (T2D) in adults.	Rapid Review Complete	23rd January 2024
-	Fingolimod	Gilenya®	For the treatment of highly active relapsing-remitting multiple sclerosis.	Full Assessment Complete	22nd September 2011
-	Fluocinolone acetonide intravitreal implant	Iluvien®	For the treatment of vision impairment associated with chronic diabetic macular oedema (DMO) considered insufficiently responsive to available therapies.	Rapid Review Complete	1st March 2016